Health Catalyst, Inc. (NASDAQ:HCAT) Insider Linda Llewelyn Sells 6,442 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $7.88, for a total value of $50,762.96. Following the transaction, the insider now owns 98,702 shares of the company’s stock, valued at approximately $777,771.76. This represents a 6.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Linda Llewelyn also recently made the following trade(s):

• On Tuesday, October 15th, Linda Llewelyn sold 1,324 shares of Health Catalyst stock. The stock was sold at an average price of $8.16, for a total value of $10,803.84.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $7.27 on Thursday. The stock’s 50-day simple moving average is $8.15 and its 200-day simple moving average is $7.45. The firm has a market capitalization of $442.36 million, a PE ratio of -5.39 and a beta of 1.31. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.22) EPS. As a group, equities research analysts forecast that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on HCAT. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Royal Bank of Canada raised their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Piper Sandler reiterated an “overweight” rating and issued a $12.00 target price (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Finally, Evercore ISI upped their price target on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, Health Catalyst has a consensus rating of “Moderate Buy” and an average price target of $11.79.

Hedge Funds Weigh In On Health Catalyst

Hedge funds have recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in shares of Health Catalyst in the 3rd quarter valued at about $34,000. Nisa Investment Advisors LLC increased its position in Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after buying an additional 5,232 shares during the period. Quarry LP lifted its stake in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after buying an additional 2,610 shares during the last quarter. nVerses Capital LLC purchased a new stake in Health Catalyst in the third quarter valued at approximately $59,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of Health Catalyst in the second quarter valued at approximately $70,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.